Table 2.
Adverse events observed in the 12-month Mercury 1 phase 3 clinical trial of Roclatan and Rhopressa. Patients with known contraindications or hypersensitivity to latanoprost were excluded.124
| Adverse Event (≥5.0% in any group) | Netarsudil 0.02%/Latanoprost 0.005% q.d. (n=243) | Netarsudil 0.02% q.d. (n=243) | Latanoprost 0.005% q.d. (n=237) |
|---|---|---|---|
| Conjunctival Hyperemia | 150 (63.0%) | 125 (51.4%) | 52 (21.9%) |
| Conjunctival Hemorrhage | 31 (13.0%) | 44 (18.1%) | 3 (1.3%) |
| Cornea Verticillata | 42 (17.6%) | 33 (13.6%) | 0 |
| Eye Pruritus | 27 (11.3%) | 22 (9.1%) | 3 (1.3%) |
| Punctate Keratitis | 12 (5.0%) | 18 (7.4%) | 10 (4.2%) |
| Increased Lacrimation | 17 (7.1%) | 20 (8.2%) | 1 (0.4%) |
| Reduced Visual Acuity | 13 (5.5%) | 13 (5.3%) | 6 (2.5%) |
| Blurred Vision | 11 (4.6%) | 15 (6.2%) | 3 (1.3%) |
| Instillation Site Pain | 55 (23.1%) | 60 (24.7%) | 18 (7.6%) |